For citations:
Pawsey A., Mahalingam P., Senthivel N., Ramessur A., Turnbull E., Usman S., Browne R., Patel A., Stewart A., Tookman L., Counsell N., Miller R., Nicum S., Eminowicz G. Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab. Tumors of female reproductive system. 2025;21(1):123-131. (In Russ.) https://doi.org/10.17650/1994-4098-2025-21-1-123-131
Email this article 